|
|
|
Issue Open Date
|
NA
|
|
|
|
Issue Closing Date
|
NA
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
-
|
|
|
|
Minimium Application No.
|
|
|
|
|
Issue Size (Shares)
|
|
|
|
|
Market Lot
|
|
|
|
|
|
|
Objective
|
|
(i) meeting product registration expenses;(ii) meeting capital expenses; and(iii) meeting expenses towards general corporate purposes.
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
|
|
|
|
Qualified Institutional Buyers
|
|
|
|
|
Retail Individual Investors
|
|
|
|
|
|
|
|
Business Description
We are a leading, vertically integrated Indian pharmaceutical company with global operations, engaged in the development, manufacture and marketing of pharmaceutical formulations and are headquartered in India.We are currently ranked as the 13th largest pharmaceutical company in India in terms of market share, based on domestic sales of formulations. (Source: IMS Health India, Secondary Stockist Audit (?SSA?), December 2010.). We are present in various major therapy areas such as those relating to neurology, psychiatry, cardiology, pain management, gastroenterology, diabetology, nephrology, urology, anti-infective therapy, dermatology, gynecology, respiratory system and ophthalmology with a strong focus on chronic therapy areas relating to neurology, psychiatry, cardiology and diabetology. We are the seventh largest player in chronic therapy areas with a 4.5% market share. (Source: IMS Health India SSA, August 2010.) We have recently extended our presence into therapy areas such as those relating to gynecology, infertility, arthritis and the respiratory system. We have also been present in the veterinary medicines business since 1997.Our products are marketed in over 50 countries, either directly, through our subsidiaries or indirectly, through arrangements with various leading global pharmaceutical companies for the distribution of our products. As of December 31, 2010, we held over 1,250 active product registrations in various markets, including the United States, Europe, Canada, Brazil, Mexico, Australia and South Africa. We have a strong product basket and pipeline and have established marketing infrastructure to develop our business in Europe and the United States, which we intend to develop as a growth driver in the future.We believe that our continuing R&D initiatives have strengthened our product offerings in the Indian and international markets. Our R&D team is developing two novel formulations to be launched in the Indian market. We have also in-licensed a lipid-based new drug delivery system (?NDDS?) platform, based on which we have developed and commercialized three pharmaceutical formulations in India. We are also taking steps to introduce these products in the international markets.Our subsidiary, Intas Biopharmaceuticals Limited (?IBPL?), which we acquired in December 2010, has investments worth ` 3,224.0 million, including in in-house development and manufacturing of products based on recombinant DNA. IBPL‘s products relate to various therapy areas, including high-growth therapy areas such as oncology, nephrology and arthritis. It has currently developed and fully commercialized five products in India and other semi-regulated markets in Africa, Latin America and Asia Pacific and has an additional 11 projects at advanced stages of development, of which, nine projects are for the Indian market and two for regulated markets. These projects are based on recombinant DNA and include five MABs. IBPL operates a biopharmaceutical manufacturing facility that was the first facility in India to be inspected and was previously approved by European authorities in 2006.We own and operate ten manufacturing facilities, of which eight are located in India, one in Mexico and a retesting laboratory, QP (qualified person) release site and fully automated packaging plant and warehouse at our facility in the U.K. Amongst them, our facilities have received approvals from various prominent international regulatory bodies, including from the United States Food and Drug Administration (?FDA?). We believe that each of our facilities is designed, equipped and operated to deliver high quality products within defined cost and delivery schedules.Our consolidated total income and profit after tax for fiscal 2010 were ` 16,259.6 million and ` 2,063.6 million, respectively, representing growth of 43.1% and 124.8%, respectively, as compared to fiscal 2009. Our consolidated total income and profit after tax for the six-month period ended September 30, 2010 were ` 9,249.2 million and ` 1,258.5 million, respectively, representing growth of 17.7% and 5.7%, respectively, as compared to the six-month period ended September 30, 2009. Our domestic and international pharmaceutical sales contributed 61.4% and 35.6%, respectively, of our sales for fiscal 2010 and 68.3% and 28.6%, respectively, of our sales for the six-month period ended September 30, 2010 (the balance of our sales are comprised of sales of services, which are not divided into domestic and international sales).
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
|
|
|
|
Offered to Public
|
|
|
|
|
Promoter's Holding (Pre-Issue)
|
|
|
|
|
Promoter's Holding (Post-Issue)
|
|
|
|
|
|
|
|
|
|
|
|
Address |
2nd Floor
Chinubhai Centre
Off. Nehru Bridge
Ashram Road
Ahmedabad,
Gujarat,
380009
Phone : 91-079-26576655
Email : manoj_nair@intaspharma.com
Website : www.intaspharma.com
|
|
|
Registrar |
|
|
|
Listed at |
|
|
|
|
Lead Manager |
Kotak Mahindra Capital Co Ltd
Morgan Stanley India Co Pvt Ltd
|
|
|
Promoters |
Bina Chudgar
Bindi Chudgar
Binish Chudgar
Equatorial Pvt Ltd
Hashmukh Chudgar
Intas Enterprise Pvt Ltd
Kusum Chudgar
Nimish Chudgar
Parul Chudgar
Shail Chudgar
Urmish Chudgar
|
|
